Le Lézard
Classified in: Health
Subjects: NPT, PER, VET, DEI

GARY SINISE FOUNDATION (GSF) ANNOUNCES THE DEPARTURE OF CEO DR. MIKE THIRTLE


GSF's Chief Philanthropy Officer, Donna Palmer, will assume day-to-day leadership of the Foundation

NASHVILLE, Tenn., Aug. 22, 2022 /PRNewswire/ -- The Gary Sinise Foundation announced today the departure of Dr. Mike Thirtle, an accomplished business and non-profit executive and retired member of the U.S. Air Force, who has served as the organization's Chief Executive Officer since July 2021, leading the foundation through a swift and significant relocation of its headquarters from Woodland Hills, California to Franklin, Tennessee.

"We faced a tough set of competing tasks in growing the foundation to another level while also relocating our first-rate team," said Founder and Chairman Gary Sinise.  "The board and I will be forever grateful to Mike for his work in helping the Foundation through this transition." 

GSF's Chief Philanthropy Officer, Donna Palmer, will assume day-to-day leadership of the Foundation. Palmer has had a distinguished career in philanthropy, helping to grow and guide a number of our nation's leading nonprofits, including St. Jude Children's Research Hospital, The American Diabetes Association, and the LIVESTRONG Foundation. She has been instrumental in the foundation's rapid growth over the past year and will serve as the interim executive director.

Established in 2011 by award-winning actor and humanitarian Gary Sinise, the Gary Sinise Foundation's mission is to serve our nation by honoring our defenders, veterans, first responders, their families, and those in need. The Foundation achieves its mission through programs and initiatives designed to entertain, educate, inspire, strengthen, and build communities. For more information, please visit GarySiniseFoundation.org.

SOURCE Gary Sinise Foundation


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: